Vaccines: [with 20 tables]
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
1999
|
| Schriftenreihe: | Handbook of experimental pharmacology
133 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXV, 534 S. Ill., graph. Darst. |
| ISBN: | 3540647406 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV012189799 | ||
| 003 | DE-604 | ||
| 005 | 20140403 | ||
| 007 | t | ||
| 008 | 980929s1999 gw ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 954335325 |2 DE-101 | |
| 020 | |a 3540647406 |9 3-540-64740-6 | ||
| 035 | |a (OCoLC)39764067 | ||
| 035 | |a (DE-599)BVBBV012189799 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-19 |a DE-355 |a DE-20 |a DE-12 |a DE-188 |a DE-578 | ||
| 050 | 0 | |a QP905 | |
| 050 | 0 | |a RM281 | |
| 082 | 0 | |a 615/.1 |2 21 | |
| 082 | 0 | |a 615/.372 |2 21 | |
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 084 | |a QV 4 |2 nlm | ||
| 245 | 1 | 0 | |a Vaccines |b [with 20 tables] |c contributors T. Bergström ... Ed. P. Perlmann and H. Wigzell |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 1999 | |
| 300 | |a XXV, 534 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of experimental pharmacology |v 133 | |
| 650 | 7 | |a Vaccines |2 cabt | |
| 650 | 7 | |a Pharmacology |2 cabt | |
| 650 | 7 | |a Infection |2 cabt | |
| 650 | 7 | |a Vaccins |2 gtt | |
| 650 | 4 | |a Immune System |x physiopathology | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a Vaccines |x pharmacology | |
| 650 | 4 | |a Vaccines |x therapeutic use | |
| 650 | 0 | 7 | |a Impfstoff |0 (DE-588)4026655-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Impfstoff |0 (DE-588)4026655-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Perlmann, Peter |e Sonstige |4 oth | |
| 700 | 1 | |a Bergström, Tomas |e Sonstige |4 oth | |
| 830 | 0 | |a Handbook of experimental pharmacology |v 133 |w (DE-604)BV002390716 |9 133 | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008261306&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-008261306 | |
Datensatz im Suchindex
| _version_ | 1807323340787941376 |
|---|---|
| adam_text |
CONTENTS
CHAPTER
1
VACCINES:
PAST,
PRESENT
AND
FUTURE
G.
S
CHILD
,
M.
C
ORBEL
,
P.
C
ORRAN
,
AND
P.
M
INOR
.
1
A.
BACTERIAL
VACCINES:
PAST,
PRESENT
AND
FUTURE
.
1
I.
PAST
.
1
II.
PRESENT
.
4
1.
PURIFIED
SUB-UNIT
VACCINES
.
5
A)
POLYSACCHARIDES
.
5
B)
PROTEIN-POLYSACCHARIDE
CONJUGATE
VACCINES
.
5
2.
PURIFIED
PROTEIN
SUB-UNITS
.
6
3.
GENETICALLY
MODIFIED
STRAINS
.
7
III.
FUTURE
.
.
.
.
.
7
1.
SYNTHETIC
PEPTIDES
.
7
2.
ANTI-IDIOTYPES
.
8
3.
NUCLEIC
ACIDS
.
8
4.
LIVE
RECOMBINANTS
.
8
5.
MULTIVALENT
COMBINATIONS
.
9
6.
SLOW-RELEASE/SINGLE-DOSE
VACCINES
.
9
7.
ORAL/MUCOSAL
DELIVERY
SYSTEMS
.
9
B.
VIRAL
VACCINES
.
10
I.
PAST
.
10
II.
PRESENT
.
11
III.
FUTURE
.
13
C.
PARASITE
VACCINES
.
14
I.
PAST
.
14
II.
PRESENT
.
14
1.
KILLED
AND
ATTENUATED
VACCINES
.
15
2.
PEPTIDE
VACCINES
.
15
3.
VACCINES
BASED
ON
EXPRESSED
PARASITE
PROTEINS
.
15
4.
LIVE
CARRIERS
.
16
5.
OTHER
APPROACHES
.
16
III.
FUTURE
.
16
1.
DNA
VACCINES
.
17
2.
ADJUVANTS
.
17
REFERENCES
.
17
XII
CONTENTS
CHAPTER
2
IMMUNOLOGY
OF
INFECTION
S.H.E.
K
AUFMANN
AND
J.
R
EIMANN
.
WITH
4
FIGURES
.
21
A.
INTRODUCTION
.
21
B.
THE
ADAPTIVE
(ACQUIRED)
IMMUNE
RESPONSE
.
22
C.
THE
CELLULAR
IMMUNE
SYSTEM:
T
CELLS
.
23
I.
MHC-RESTRICTED
PRESENTATION
OF
EPITOPES
TO
T
CELLS
.
23
II.
CONVENTIONAL
MHC-I
OR
MHC-II
RESTRICTED
TCRA/5
T
CELLS
.
24
III.
CONVENTIONAL
MHC-IA
RESTRICTED
CD8
+
TCRA/F
T
CELLS
.
27
IV.
UNCONVENTIONAL
MHC-IB
RESTRICTED
CD8
+
TCRA/3
T
CELLS
.
28
V.
UNCONVENTIONAL
DOUBLE-NEGATIVE
(DN,
CD4
"
CD8
),
CDL-RESTRICTED
TCRA/3
T
CELLS
.
28
VI.
UNCONVENTIONAL
CDL-RESTRICTED
CD4
+
OR
DN
NK1
+
TCRA/3
T
CELLS
.
29
VII.
TCRYD
T
CELLS
.
29
D.
CYTOKINES
.
30
E.
THE
EARLY
DECISION
ON
THE
TYPE
OF
EFFECTOR
FUNCTIONS
THAT
PREVAIL
IN
AN
IMMUNE
RESPONSE
.
33
F.
THE
HUMORAL
IMMUNE
SYSTEM:
B
CELLS
.
34
G.
T
AND
B
CELL
MEMORY
.
35
H.
MUCOSAL
IMMUNITY
.
35
I.
UNSUCCESSFUL
INDUCTION
OF
SPECIFIC
IMMUNE
RESPONSES
.
36
J.
IMPLICATIONS
FOR
RATIONAL
VACCINE
DESIGN
.
37
REFERENCES
.
39
CHAPTER
3
DNA
VACCINES:
IMMUNOGENICITY
AND
PRECLINICAL
EFFICACY
J.B.
U
LMER
,
J.J.
D
ONNELLY
,
AND
M.A.
LIU
.
43
A.
OVERVIEW
.
43
B.
BACKGROUND
.
43
C.
EFFECTIVENESS
OF
DNA
VACCINES
IN
ANIMAL
MODELS
.
45
I.
MISCELLANEOUS
.
45
II.
FERRETS
.
45
III.
NONHUMAN
PRIMATES
.
46
D.
MUCOSAL
IMMUNIZATION
.
48
E.
DELIVERY
SYSTEMS
AND
ADJUVANTS
.
50
I.
DNA
DELIVERY
.
50
II.
DNA
AS
ADJUVANT
.
50
F.
SUMMARY
.
52
REFERENCES
.
52
CONTENTS
-
XIII
CHAPTER
4
ANTIGEN-PRESENTATION
SYSTEMS,
IMMUNOMODULATORS,
AND
IMMUNE
RESPONSES
TO
VACCINES
C.-A.
S
IEGRIST
AND
P.-H.
L
AMBERT
.
57
A.
FROM
EMPIRICAL
APPROACHES
TO
RATIONALLY
SELECTED
ANTIGEN
PRESENTATION
SYSTEMS
AND
IMMUNOMODULATORS
FOR
VACCINE
MEDIATED
PROTECTION
AGAINST
INFECTIOUS
DISEASES
.
57
B.
WHAT
ARE
THE
ESSENTIAL
PARAMETERS
OF
VACCINE-INDUCED
EFFECTOR
MECHANISMS?
.
59
I.
ANTIBODY-MEDIATED
VACCINE
RESPONSES
.
59
II.
VACCINE-SPECIFIC
T
CELL
RESPONSES
.
61
1.
CD4
T
CELL
VACCINE
RESPONSES
.
61
2.
CHARACTERISTICS
OF
VACCINE-SPECIFIC
CD8
CYTOTOXIC
RESPONSES
.
61
C.
WHAT
FUNDAMENTAL
IMMUNOLOGICAL
MECHANISMS
CAN
BE
MODULATED
BY
ANTIGEN-DELIVERY
SYSTEMS
AND
IMMUNOMODULATORS?
.
62
I.
MODULATION
OF
ANTIGEN
PRESENTATION
TO
T/B
CELLS
.
62
1.
ANTIGEN
CONFORMATION
.
62
2.
ANTIGEN
PERSISTENCE
.
63
3.
TARGETING
OF
PROFESSIONAL
ANTIGEN-PRESENTING
CELLS
.
64
II.
MODULATION
OF
CD4
T
CELL
RESPONSES
.
64
III.
INDUCTION
OF
CD8
T
CELL
RESPONSES
.
65
D.
WHAT
IS
THE
EFFECT
OF
SPECIFIC
DELIVERY
SYSTEMS
AND
IMMUNOMODULATORS
ON
RESPONSES
TO
VACCINE
ANTIGENS?
.
65
I.
EFFECT
OF
ANTIGEN-DELIVERY
SYSTEMS
.
65
1.
LIVE
BACTERIAL
AND
VIRAL
VECTORS
.
65
A)
BACTERIAL
VECTORS
.
65
B)
VIRAL
VECTORS
.
66
2.
DNA
VACCINES
.
67
II.
EFFECT
OF
PARTICULATE
SUBSTANCES
ON
VACCINE
RESPONSES
.
68
1.
ALUMINUM
AND
CALCIUM
SALTS
.
68
2.
WATER
AND
OIL
EMULSIONS
.
69
3.
LIPOSOMES
AND
VIROSOMES
.
69
4.
PROTEOSOMES
.
70
5.
MICRO
AND
NANOSPHERES
OF
BIODEGRADABLE
POLYMERS
.
70
III.
EFFECT
OF
IMMUNOMODULATORS
THAT
CAN
BE
INCORPORATED
INTO
ANTIGEN-PRESENTATION
SYSTEMS
.
71
1.
LIPID
A
AND
DERIVATIVES
.
72
2.
SAPONINS
(QUIL
A,
QS21)
.
72
3.
NONIONIC
BLOCK
COPOLYMERS
.
72
4.
MDP
AND
DERIVATIVES
.
73
5.
CYTOKINES
AND
INTERFERONS
.
73
XIV
CONTENTS
IV.
EFFECT
OF
VACCINE
FORMULATIONS
THAT
COMBINE
ANTIGEN-DELIVERY
SYSTEMS
AND
IMMUNOMODULATORY
SUBSTANCES
.
74
1.
IMMUNE-STIMULATING
COMPLEXES
.
74
2.
W/O
EMULSIONS
WITH
BUILT-IN
IMMUNOMODULATORS
.
75
3.
O/W
EMULSIONS
WITH
BUILT-IN
IMMUNOMODULATORS
.
76
4.
FORMULATIONS
BASED
ON
LIPOSOMES
WITH
BUILT-IN
IMMUNOMODULATORS
.
77
E.
HOW
CAN
VACCINES
BE
DESIGNED
FOR
SELECTED
TARGET
POPULATIONS
WITH
VARIABLE
LEVELS
OF
IMMUNOCOMPETENCE?
.
77
I.
INDUCING
EFFICIENT
VACCINE
RESPONSES
IN
EARLY
LIFE
.
77
1.
CHARACTERISTICS
OF
IMMUNE
RESPONSES
IN
EARLY
LIFE
.
77
2.
SELECTING
ANTIGEN-PRESENTATION
SYSTEMS/
IMMUNOMODULATORS
FOR
USE
IN
EARLY
LIFE
.
78
A)
INDUCING
PROTECTIVE
ANTIBODY
RESPONSES
IN
INFANTS
AND
NEONATES
.
79
B)
INDUCING
STRONG
TH1
AND
CTL
RESPONSES
IN
INFANTS
AND
NEONATES
.
79
C)
INDUCING
VACCINE
RESPONSES
IN
PRESENCE
OF
MATERNAL
ANTIBODIES
.
80
II.
INDUCING
EFFICIENT
VACCINE
RESPONSES
IN
THE
ELDERLY
.
81
III.
INDUCING
EFFICIENT
VACCINE
RESPONSES
IN
IMMUNODEFICIENT
PATIENTS
.
82
1.
ENHANCING
VACCINE
RESPONSES
IN
IMMUNOSUPPRESSED
PATIENTS
.
82
2.
ENHANCING
VACCINE
RESPONSES
IN
HIV-1
INFECTED
PATIENTS
.
82
F.
CONCLUSIONS
.
83
REFERENCES
.
84
CHAPTER
5
VACCINES
AGAINST
MEASLES,
MUMPS,
RUBELLA,
AND
VARICELLA
E.
N
ORRBY
.
93
A.
INTRODUCTION
.
93
B.
MEASLES
VACCINE
.
94
I.
SAFETY
AND
EFFICACY
OF
LIVE
MEASLES
VACCINE
.
95
II.
EPIDEMIOLOGICAL
CONSEQUENCES
OF
USING
LIVE
MEASLES
VACCINE
.
97
III.
NEW
KINDS
OF
MEASLES
VACCINES
.
99
IV.
REMAINING
PROBLEMS
IN
USING
MEASLES
VACCINE
AND
PROJECTED
FUTURE
DEVELOPMENTS
.
99
C.
MUMPS
VACCINE
.
100
I.
SAFETY
AND
EFFICACY
OF
LIVE
MUMPS
VACCINE
.
101
CONTENTS
XV
II.
EPIDEMIOLOGICAL
CONSEQUENCES
OF
USING
LIVE
MUMPS
VACCINE
USE
.
102
III.
NEW
KINDS
OF
MUMPS
VACCINES
.
103
IV.
REMAINING
PROBLEMS
IN
USING
MUMPS
VACCINE
AND
PROJECTED
FUTURE
DEVELOPMENTS
.
103
D.
RUBELLA
VACCINE
.
103
I.
SAFETY
AND
EFFICACY
OF
LIVE
RUBELLA
VACCINE
.
104
II.
EPIDEMIOLOGICAL
CONSEQUENCES
OF
USING
LIVE
RUBELLA
VACCINE
.
106
III.
NEW
KINDS
OF
RUBELLA
VACCINES
.
106
IV.
REMAINING
PROBLEMS
IN
USING
RUBELLA
VACCINE
AND
PROJECTED
FUTURE
DEVELOPMENTS
.
107
E.
VARICELLA
VACCINE
.
108
I.
SAFETY
AND
EFFICACY
OF
LIVE
VARICELLA
VACCINE
.
109
II.
EPIDEMIOLOGICAL
CONSEQUENCES
OF
USING
LIVE
VARICELLA
VACCINE
.
110
III.
NEW
KINDS
OF
VARICELLA
VACCINES
.
ILL
IV.
REMAINING
PROBLEMS
IN
USING
VARICELLA
VACCINE
AND
PRIORITIES
FOR
THE
FUTURE
.
112
F.
EPILOGUE
.
112
REFERENCES
.
113
CHAPTER
6
HEPATITIS
AND
POLIO
VACCINES
F.
S
CHODEL
AND
P.
M
INOR
.
WITH
3
FIGURES
.
121
A.
INTRODUCTION
.
121
B.
HEPATITIS
A
VIRUS
.
122
I.
THE
VIRUS
.
122
II.
THE
ANTIGENS
.
122
III.
THE
DISEASE
.
123
IV.
IMMUNITY
AND
VACCINES
.
124
1.
PASSIVE
IMMUNIZATION
.
124
2.
INACTIVATED
WHOLE
VIRUS
VACCINES
.
124
3.
LIVE
ATTENUATED
VACCINES
.
126
C.
HEPATITIS
B
VIRUS
.
126
I.
THE
VIRUS
.
126
II.
THE
ANTIGENS
.
127
1.
ENVELOPE
PROTEINS
.
127
2.
NUCLEOCAPSID
ANTIGEN
.
128
III.
THE
DISEASE
.
129
IV.
IMMUNITY
AND
VACCINES
.
131
1.
PROTECTIVE
IMMUNITY
.
131
2.
PASSIVE
IMMUNIZATION
.
131
3.
ACTIVE
IMMUNIZATION
.
131
XVI
CONTENTS
A)
TARGETS
.
131
B)
CURRENT
VACCINES:
PLASMA-DERIVED
VACCINES
.
131
C)
RECOMBINANT
VACCINES
.
133
A)
HBSAG-BASED
.
133
|3)
PRE-S
CONTAINING
VACCINES
.
135
Y)
ALTERNATIVE
VACCINATION
APPROACHES
.
138
B)
THERAPEUTIC
VACCINATION?
.
143
E)
ERADICATION
OF
HEPATITIS
B?
.
145
D.
HEPATITIS
C
VIRUS
.
145
I.
THE
VIRUS
.
145
II.
THE
ANTIGENS
.
146
III.
THE
DISEASE
.
146
IV.
VACCINE
DEVELOPMENT
.
147
E.
HEPATITIS
E
VIRUS
.
147
I.
THE
VIRUS
.
147
II.
THE
ANTIGENS
.
148
III.
THE
DISEASE
.
148
IV.
CANDIDATE
VACCINES
.
148
F.
POLIOVIRUS
.
148
I.
THE
VIRUS
.
148
II.
THE
ANTIGENS
.
149
III.
THE
DISEASE
.
150
IV.
INACTIVATED
POLIOVACCINES
.
151
V.
ORAL
POLIOVACCINES
.
152
VI.
ERADICATION
OF
POLIOMYELITIS
.
154
REFERENCES
.
157
CHAPTER
7
HERPES
A.
V
AHLNE
,
T.
B
ERGSTROM
,
AND
B.
S
VENNERHOLM
.
171
A.
HERPESVIRIDAE
.
171
B.
HISTORICAL
BACKGROUND
.
172
I.
HSV
.
172
II.
CMV
.
173
III.
EBV
.
173
C.
THE
GLYCOPROTEINS
.
173
D.
EARLY
EVENTS
OF
HUMAN
HERPES
VIRUS
REPLICATION
.
175
E.
LATENCY
.
176
F.
REACTIVATION
.
177
G.
CLINICAL
INFECTIONS
.
179
I.
HSV
.
179
II.
CMV
.
180
III.
EBV
.
181
CONTENTS
XVII
H.
IMMUNOLOGY
.
181
I.
THERAPEUTIC
VACCINES
.
183
I.
KILLED
VACCINES
.
183
II.
SUBUNIT
VACCINES
.
184
J.
PROPHYLACTIC
VACCINES
.
185
I.
HSV
.
185
II.
CMV
.
186
1.
LIVE
VACCINE
.
187
2.
SUBUNIT
VACCINE
.
187
III.
EBV
.
188
1.
SUBUNIT
VACCINES
.
188
2.
LIVE
VACCINES
.
188
K.
CONCLUSIONS
.
189
REFERENCES
.
189
CHAPTER
8
TOXIN-BASED
VACCINES
(DIPHTHERIA,
TETANUS,
PERTUSSIS)
R.
R
APPUOLI
AND
M.
P
IZZA
.
201
A.
INTRODUCTION
.
201
B.
DIPHTHERIA
TOXIN
.
202
C.
TETANUS
TOXIN
.
203
D.
PRODUCTION,
EFFECTIVENESS,
AND
PROBLEMS
OF
CONVENTIONAL
DIPHTHERIA
AND
TETANUS
VACCINES
.
204
I.
PRODUCTION
AND
DETOXIFICATION
OF
DIPHTHERIA
AND
TETANUS
TOXOIDS
.
204
II.
PRODUCTION
AND
DETOXIFICATION
OF
PURIFIED
DIPHTHERIA
AND
TETANUS
TOXOIDS
.
205
E.
FUTURE
PROSPECTS
.
206
I.
ENGINEERED
LIVE-ATTENUATED
STRAINS
.
206
II.
RECOMBINANT
MOLECULES
.
207
III.
MUCOSAL
VACCINATION
.
207
IV.
CRM
197
.
208
F.
DIPHTHERIA
AND
TETANUS
TOXOIDS
AS
CARRIERS
FOR
POLYSACCHARIDE
VACCINES
.
209
G.
PERTUSSIS
.
209
I.
THE
DISEASE
.
209
II.
HISTORY
OF
ACELLULAR
VACCINES
.
210
III.
PERTUSSIS
TOXIN
.
211
IV.
GENETIC
DETOXIFICATION
.
211
V.
ACELLULAR
VACCINES
PROPOSED
.
212
VI.
CLINICAL
TRIALS
.
212
VIL
OTHER
CLINICAL
STUDIES
.
217
REFERENCES
.
218
XVIII
CONTENTS
CHATER
9
OUTER
MEMBRANE
PROTEIN
VACCINES
J.
P
OOLMAN
.
225
A.
INTRODUCTION
.
225
B.
NEISSERIA
GONORRHOEAE
.
225
I.
PILI
.
225
II.
OUTER
MEMBRANE
PROTEIN
PI
OR
POR
.
226
III.
PII
OR
OPACITY-ASSOCIATED
PROTEINS
.
227
IV.
LIPOPOLYSACCHARIDES
.
227
V.
FE
LIMITATION
INDUCIBLE
OMPS
.
228
VI.
MISCELLANEOUS
.
228
C.
NEISSERIA
MENINGITIDIS
.
229
I.
THE
SEROGROUP
B
CAPSULAR
POLYSACCHARIDE
.
229
II.
OMP
VACCINES
.
230
III.
OPA
AND
OPC
.
233
IV.
PILI
.
233
V.
LIPOPOLYSACCHARIDES
.
233
VI.
FE
LIMITATION
INDUCIBLE
OMPS
.
234
VIL
MISCELLANEOUS
.
234
D.
NONTYPABLE
HAEMOPHILUS
INFLUENZAE
.
234
I.
PL,
P2,
P4
.
235
II.
P6
AND
PCP
.
235
III.
PILI,
FIMBRIAE,
P5
.
235
IV.
HIGH
MOLECULAR
WEIGHT
ADHESINS
.
235
V.
LIPOPOLYSACCHARIDE
OR
LIPO-OLIGOSACCHARIDE
.
236
VI.
FE
LIMITATION
INDUCIBLE
OMPS
.
236
VIL
MISCELLANEOUS
.
236
E.
MORAXELLA
CATARRHALIS
.
236
I.
OMP
CD,
OMP
E
.
237
II.
PILI/FIMBRIAE/HIGH
MOLECULAR
WEIGHT
OMPS
.
237
III.
LIPOPOLYSACCHARIDE
OR
LIPO-OLIGOSACCHARIDE
.
237
IV.
FE
LIMITATION
INDUCIBLE
OMPS
.
237
F.
ANIMAL
MODELS
.
237
REFERENCES
.
238
CHAPTER
10
CARBOHYDRATE-BASED
BACTERIAL
VACCINES
J.T.
P
OOLMAN
,
C.
L
AFERRIERE
,
AND
S.B.
S
VENSON
.
249
A.
INTRODUCTION
.
249
B.
THE
HIB
EXPERIENCE
.
250
C.
MENINGOCOCCAL
POLYSACCHARIDE
AND
CONJUGATE
VACCINES
.
252
D.
PNEUMOCOCCAL
POLYSACCHARIDE
AND
CONJUGATE
VACCINES
.
253
I.
PROTEIN
CARRIER
.
254
CONTENTS
XIX
II.
POLYSACCHARIDE
SIZE
.
255
III.
COUPLING
CHEMISTRY
.
255
IV.
POLYSACCHARIDE-PROTEIN
RATIO
.
255
V.
ADJUVANT
.
256
VI.
ANIMAL
MODELS
AND
CORRELATES
OF
PROTECTION
.
256
VII.
CLINICAL
TRIALS
OF
PNEUMOCOCCAL
POLYSACCHARIDE-PROTEIN
CONJUGATE
VACCINES
.
257
VIII.
THE
FUTURE
OF
PNEUMOCOCCAL
VACCINES
.
259
E.
SALMONELLA,
SHIGELLA,
AND
E.
COLL
.
259
I.
SALMONELLA:
O-ANTIGEN
SPECIFIC
CONJUGATES
.
259
II.
S.
TYPHI:
VI-ANTIGEN
SPECIFIC
CONJUGATES
.
261
III.
SHIGELLA:
O-ANTIGEN
SPECIFIC
CONJUGATES
.
261
IV.
E.
COLI:
O-ANTIGEN
SPECIFIC
CONJUGATES
.
262
REFERENCES
.
262
CHAPTER
11
MYCOBACTERIA
R.
J
ANSSEN
,
D.
Y
OUNG
,
AND
J.
T
HOLE
.
273
A.
INTRODUCTION
.
273
B.
THE
CELLULAR
RESPONSE
TO
MYCOBACTERIA
.
273
I.
MACROPHAGE
INTERACTIONS
.
273
II.
RECOGNITION
BY
CD4
T
CELLS
.
275
III.
THE
CD8
RESPONSE
.
276
IV.
OTHER
SUBSETS
.
277
C.
MYCOBACTERIAL
ANTIGENS
.
278
D.
PROTECTION
VERSUS
DISEASE
.
279
E.
MYCOBACTERIAL
VACCINES
.
280
I.
LIVE
VACCINES
.
280
II.
SUBUNIT
VACCINES
.
282
III.
DNA
VACCINES
.
283
F.
FUTURE
PROSPECTS
.
284
REFERENCES
.
284
CHAPTER
12
VACCINES
AGAINST
DIARRHEAL
DISEASES
J.
H
OLMGREN
AND
A.-M.
S
VENNERHOLM
.
291
A.
INTRODUCTION
.
291
B.
OVERVIEW
OF
THE
MAIN
DIARRRHEAL
PATHOGENS
.
293
I.
VIBRIO
CHOLERAE
.
293
II.
ENTEROTOXIGENIC
ESCHERICHIA
COLI
.
294
III.
SHIGELLA
SPP
.
294
IV.
CAMPYLOBACTER
JEJUNI
.
295
V.
ROTAVIRUS
.
295
XX
CONTENTS
C.
MECHANISMS
OF
DISEASE
AND
IMMUNITY
IN
DIARRHEAL
DISEASES
.
295
I.
ENTEROTOXINS
AND
ANTITOXIC
IMMUNITY
.
296
II.
COLONIZATION
AND
ANTIBACTERIAL
IMMUNITY
IN
CHOLERA
AND
ETEC
INFECTIONS
.
297
III.
PATHOGENIC
AND
IMMUNE
MECHANISMS
IN
SHIGELLA
INFECTIONS
.
299
IV.
PROTECTIVE
IMMUNITY
IN
ROTAVIRUS
INFECTIONS
.
301
D.
CHOLERA
VACCINES
.
302
I.
ORAL
INACTIVATED
VACCINES
.
302
II.
ORAL
LIVE
VACCINES
.
305
III.
COMBINED
VACCINES
AGAINST
O1
AND
0139
CHOLERA
.
307
E.
ETEC
VACCINES
.
308
I.
ORAL
INACTIVATED
VACCINES
.
309
II.
ORAL
LIVE
VACCINES
.
313
F.
SHIGELLA
VACCINES
.
314
I.
PARENTERAL
VACCINES
.
315
II.
ORAL
LIVE
VACCINES
.
315
G.
CAMPYLOBACTER
JEJUNI
VACCINES
.
317
H.
ROTAVIRUS
VACCINES
.
318
REFERENCES
.
321
CHAPTER
13
SEXUALLY
TRANSMITTED
DISEASES
E.G.
S
ANDSTROM
.
329
A.
INTRODUCTION
.
329
B.
SPECIAL
CHALLENGES
.
330
C.
GONORRHEA
.
331
I.
EPIDEMIOLOGY
.
331
II.
NATURAL
INFECTION
.
331
III.
ANTIGENIC
VARIATION
.
332
IV.
WHOLE-CELL
VACCINES
.
332
V.
SUBCOMPONENT
VACCINES
.
332
1.
PORIN
.
332
2.
LIPO-OLIGOSACCHARIDES
.
333
3.
PILI
.
333
4.
OPACITY
PROTEINS
.
334
5.
TRANSFERRIN
BINDING
PROTEINS
.
334
6.
IGA
PROTEASE
.
334
VI.
PROSPECTS
.
334
D.
CHLAMYDIA
INFECTION
.
335
I.
EPIDEMIOLOGY
.
335
II.
NATURAL
INFECTION
.
335
III.
PATHOGENESIS
.
336
CONTENTS
XXI
IV.
WHOLE-CELL
VACCINES
.
336
V.
SUBCOMPONENT
VACCINES
.
337
1.
MAJOR
OUTER
MEMBRANE
PROTEIN
.
337
2.
HEAT
SHOCK
PROTEIN
75
KDA
.
338
VI.
PROSPECTS
.
338
E.
GENITAL
ULCERS
CAUSED
BY
HAEMOPHILUS
DUCREYI
.
339
I.
EPIDEMIOLOGY
.
339
II.
NATURAL
INFECTION
.
339
III.
SUBCOMPONENT
VACCINES
.
339
IV.
PROSPECTS
.
340
F.
SYPHILIS
.
340
I.
EPIDEMIOLOGY
.
340
II.
NATURAL
INFECTION
.
340
III.
ANTIGENIC
VARIATION
.
341
IV.
WHOLE-CELL
VACCINES
.
341
V.
SUBCOMPONENT
VACCINES
.
341
1.
CARDIOLIPIN
.
341
2.
TREPONEMAL
PROTEINS
.
341
VI.
PROSPECTS
.
342
G.
HUMAN
GENITAL
PAPILLOMA
VIRUS
INFECTION
.
342
I.
EPIDEMIOLOGY
.
342
II.
NATURAL
INFECTION
.
342
III.
WHOLE-VIRAL
VACCINES
.
343
IV.
SUBCOMPONENT
VACCINES
.
343
V.
PROSPECTS
.
344
H.
HERPES
SIMPLEX
INFECTION
.
344
I.
EPIDEMIOLOGY
.
344
II.
NATURAL
INFECTION
.
345
III.
WHOLE-VIRAL
VACCINES
.
345
IV.
SUBCOMPONENT
VACCINES
.
345
V.
PROSPECTS
.
347
I.
CONCLUSION
.
347
REFERENCES
.
348
CHAPTER
14
DESIGNING
A
VACCINE
AGAINST
HIV
A.M.
S
CHULTZ
.
357
A.
PERSPECTIVE
.
357
I.
THE
NEED
FOR
A
VACCINE
.
357
II.
THE
FIRST
DECADE:
1985-1995
.
357
III.
NEW
PARADIGMS
.
359
IV.
WHAT
SHOULD
THE
VACCINE
DO?
.
360
V.
DESIGN
CONSIDERATIONS
.
361
XXII
CONTENTS
B.
THE
ROLE
OF
ANTIBODY
.
362
I.
PASSIVE
TRANSFER
.
362
II.
DOES
HIV
HAVE
SEROTYPES?
.
363
III.
DO
CORECEPTOR
FAMILIES
OF
HIV
REPRESENT
SEROTYPES?
.
.
.
364
IV.
DESIGN
CONSIDERATIONS
.
365
1.
THE
IDEAL
IMMUNOGEN
.
365
2.
OBSTACLES
TO
INDUCING
A
BROAD
RESPONSE
.
366
3.
HUMAN
MONOCLONAL
ANTIBODIES
AS
CLUES
.
368
4.
IS
NEUTRALIZATION
REQUIRED
FOR
PROTECTION?
.
368
C.
THE
ROLE
OF
CYTOTOXIC
T-CELLS
.
369
I.
EVIDENCE
FROM
VACCINATION
AND
CHALLENGE
.
369
II.
EVIDENCE
FROM
INFECTION
.
370
III.
ADDRESSING
THE
HETEROGENEITY
OF
HIV
.
371
IV.
DESIGN
CONSIDERATIONS
.
372
D.
OTHER
T-CELL
ACTIVITIES
.
372
E.
MUCOSAL
IMMUNITY
.
373
F.
VACCINE
APPROACHES
.
375
I.
LIVE-ATTENUATED
VACCINE
.
375
II.
WHOLE,
INACTIVATED
VIRUS
.
376
III.
RECOMBINANT
VECTORS
.
377
IV.
PLASMID
IMMUNIZATION
.
378
V.
SUBUNIT
PROTEINS
AND
PEPTIDES
.
379
VI.
COMBINATIONS
.
379
G.
PROSPECTUS
.
380
I.
DESIGN
CONSIDERATIONS
.
380
II.
EVALUATION
CONSIDERATIONS
.
382
REFERENCES
.
382
CHAPTER
15
AN
OVERVIEW
OF
MALARIA
VACCINE
DEVELOPMENT
EFFORTS
S.
K
UMAR
,
D.C.
K
ASLOW
,
AND
S.L.
H
OFFMAN
.
WITH
1
FIGURE
.
397
A.
EPIDEMIOLOGY
.
397
B.
THE
PARASITE
.
397
C.
APPROACHES
TO
MALARIA
VACCINE
DEVELOPMENT:
PREVENTING
ERYTHROCYTIC
STAGE
INFECTION
OR
REDUCING
MORBIDITY
AND
MORTALITY
WITHOUT
PREVENTING
INFECTION
.
398
D.
PREERYTHROCYTIC
STAGE
VACCINES
.
399
I.
PREVENTING
SPOROZOITE
INVASION
OF
HEPATOCYTES
.
399
II.
ATTACKING
INFECTED
HEPATOCYTES
.
402
E.
ERYTHROCYTIC
STAGE
VACCINES:
REDUCING
PARASITE
BURDEN
AND
BLOCKING
PATHOGENESIS
.
405
I.
APPROACHES
TO
REDUCING
PARASITE
BURDEN
.
406
1.
PREVENTING
MEROZOITE
INVASION
OF
ERYTHROCYTES
.
406
CONTENTS
XXIII
2.
ATTACKING
INFECTED
ERYTHROCYTES
.
406
II.
ANTIPARASITE
IMMUNE
MECHANISMS
THAT
CONTRIBUTE
TO
PARASITE
REDUCTION
.
407
1.
REDUCTION
IN
PARASITE
BURDEN:
THE
DIRECT
EFFECTS
OF
ANTIBODIES
.
407
2.
REDUCTION
IN
PARASITE
BURDEN:
THE
ROLE
OF
CELLULAR
MECHANISMS
THROUGH
DIRECT
EFFECTS
OF
CYTOKINES
AND
OTHER
BIOACTIVE
MOLECULES
.
407
A)
THE
ROLE
OF
CD4
+
T
CELLS
.
407
B)
THE
ROLE
OF
Y/D
T
CELLS
.
409
C)
THE
ROLE
OF
CYTOKINES
.
410
III.
DATA
SUPPORTING
REDUCTION
IN
PARASITE
BURDEN
AND
THE
STATUS
OF
EXPERIMENTAL
ERYTHROCYTIC
STAGE
VACCINES
DESIGNED
TO
REDUCE
PARASITE
BURDEN
.
411
1.
MSP1
.
412
2.
MSP2
.
414
3.
AMA1
.
414
4.
EBA-175
.
415
5.
SERA
.
416
6.
RESA
.
416
7.
SYNTHETIC
SPF66
VACCINE
.
417
IV.
BLOCKING
PATHOGENESIS
.
_
.
417
1.
INHIBITING
ADHERENCE
OF
INFECTED
ERYTHROCYTES
TO
ENDOTHELIAL
CELLS
.
418
2.
INHIBITING
ADHERENCE
OF
INFECTED
ERYTHROCYTES
TO
OTHER
ERYTHROCYTES
(RESETTING)
.
419
3.
INHIBITING
MALARIA
TOXINS
.
420
F.
TRANSMISSION
BLOCKING
VACCINES
.
420
I.
GAMETE
AND
EARLY
ZYGOTE
SURFACE
TARGET
ANTIGENS
.
422
II.
LATE
ZYGOTE
OOKINETE
SURFACE
TARGET
ANTIGENS
.
422
III.
OOKINETE
SECRETED
AND
MOSQUITO
DERIVED
TARGET
ANTIGENS
.
424
IV.
PROGRESS
TOWARDS
A
TRANSMISSION
BLOCKING
VACCINE
.
425
G.
CONCLUSIONS
.
426
REFERENCES
.
426
CHAPTER
16
ANTIFERTILITY
VACCINES
V.C.
S
TEVENS
.
WITH
4
FIGURES
.
443
A.
INTRODUCTION
.
443
B.
CURRENT
STATUS
OF
VACCINE
DEVELOPMENT
.
445
I.
ANTISPERM
VACCINES
.
445
II.
OVUM
ANTIGENS
.
446
III.
ANTIHORMONE
VACCINES
.
449
XXIV
CONTENTS
1.
GONADOTROPIN-RELEASING
HORMONE
.
449
2.
FOLLICLE-STIMULATING
HORMONE
.
450
3.
HUMAN
CHORIONIC
GONADOTROPIN
.
452
C.
PROBLEMS
AND
PROSPECTS
.
456
REFERENCES
.
457
CHAPTER
17
CANCER
VACCINES
K.E.
H
ELLSTROM
AND
I.
H
ELLSTROM
.
463
A.
INTRODUCTION
.
463
B.
TUMOR
ANTIGENS
.
463
I.
RECOGNITION
BY
ANTIBODIES
.
464
II.
RECOGNITION
BY
T
LYMPHOCYTES
.
464
III.
TUMOR
PEPTIDES
AS
T
CELL
TARGETS
.
465
IV.
ANTIGEN
PRESENTATION
.
466
C.
TYPES
OF
TUMOR
VACCINES
.
468
D.
DOWNREGULATORY
MECHANISMS
.
471
E.
CONCLUSIONS
AND
OUTLOOK
.
472
REFERENCES
.
473
CHAPTER
18
PREVENTION
OF
AUTOIMMUNITY
A.J.
S
LAVIN
AND
H.L.
W
EINER
.
WITH
2
FIGURES
.
479
A.
OVERVIEW
OF
AUTOIMMUNE
DISEASES
.
479
B.
AUTOREACTIVE
T
CELLS
.
479
C.
ANTIGEN-SPECIFIC
THERAPY
.
480
I.
ALTERED
PEPTIDE
LIGANDS
.
480
II.
ORAL
TOLERANCE
.
480
1.
MECHANISMS
OF
ORAL
TOLERANCE
.
481
2.
BYSTANDER
SUPPRESSION
.
484
3.
MODULATION
OF
ORAL
TOLERANCE
.
485
III.
NASAL
AND
AEROSOL
MUCOSAL
TOLERANCE
.
487
IV.
TREATMENT
OF
AUTOIMMUNE
DISEASES
IN
ANIMALS
.
488
1.
EXPERIMENTAL
AUTOIMMUNE
ENCEPHALOMYELITIS
.
488
2.
ARTHRITIS
.
488
3.
UVEITIS
.
488
4.
MYASTHENIA
GRAVIS
.
489
5.
DIABETES
.
489
6.
TRANSPLANTATION
AND
OTHER
MODELS
.
489
V.
TREATMENT
OF
AUTOIMMUNE
DISEASES
IN
HUMANS
.
490
D.
FUTURE
DIRECTIONS
.
491
REFERENCES
.
492
CONTENTS
XXV
CHAPTER
19
VACCINES
AGAINST
ALLERGIES
L.
H
ELLMAN
.
WITH
2
FIGURES
.
499
A.
INTRODUCTION
.
499
B.
THE
ALLERGIC
IMMUNE
RESPONSE
.
499
C.
TRADITIONAL
IMMUNOTHERAPY
.
506
I.
MODIFIED
ALLERGENS
OR
ALLERGEN
EXTRACTS
.
507
II.
ORAL
ADMINISTRATION
OF
RECOMBINANT
ALLERGENS
OR
ALLERGEN
EXTRACTS
.
509
III.
PEPTIDE
VACCINES
.
510
IV.
CYTOKINE
AGONISTS
AND
ANTAGONISTS
.
512
V.
LOW
MOLECULAR
WEIGHT
COMPOUNDS
INTERFERING
WITH
THE
INTERACTION
BETWEEN
IGE
AND
ITS
HIGH-AFFINITY
RECEPTOR
.
.
513
VI.
DEPLETION
OF
PLASMA
AND
MAST
CELL
BOUND
IGE
BY
TREATMENT
WITH
MONOCLONAL
ANTI-IGE
ANTIBODIES
.
514
VII.
INDUCTION
OF
A
STRONG
ANTI-IGE
RESPONSE
BY
VACCINATION
.
.
516
D.
CONCLUSIONS
.
519
REFERENCES
.
519
SUBJECT
INDEX
.
527 |
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV012189799 |
| callnumber-first | Q - Science |
| callnumber-label | QP905 |
| callnumber-raw | QP905 RM281 |
| callnumber-search | QP905 RM281 |
| callnumber-sort | QP 3905 |
| callnumber-subject | QP - Physiology |
| classification_rvk | XI 1701 |
| ctrlnum | (OCoLC)39764067 (DE-599)BVBBV012189799 |
| dewey-full | 615/.1 615/.372 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.1 615/.372 |
| dewey-search | 615/.1 615/.372 |
| dewey-sort | 3615 11 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV012189799</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140403</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">980929s1999 gw ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">954335325</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540647406</subfield><subfield code="9">3-540-64740-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)39764067</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV012189799</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM281</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">21</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.372</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Vaccines</subfield><subfield code="b">[with 20 tables]</subfield><subfield code="c">contributors T. Bergström ... Ed. P. Perlmann and H. Wigzell</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXV, 534 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">133</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccines</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacology</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Infection</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vaccins</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immune System</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perlmann, Peter</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bergström, Tomas</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">133</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">133</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008261306&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008261306</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV012189799 |
| illustrated | Illustrated |
| indexdate | 2024-08-14T01:10:49Z |
| institution | BVB |
| isbn | 3540647406 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008261306 |
| oclc_num | 39764067 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-20 DE-12 DE-188 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-20 DE-12 DE-188 DE-578 |
| physical | XXV, 534 S. Ill., graph. Darst. |
| publishDate | 1999 |
| publishDateSearch | 1999 |
| publishDateSort | 1999 |
| publisher | Springer |
| record_format | marc |
| series | Handbook of experimental pharmacology |
| series2 | Handbook of experimental pharmacology |
| spelling | Vaccines [with 20 tables] contributors T. Bergström ... Ed. P. Perlmann and H. Wigzell Berlin [u.a.] Springer 1999 XXV, 534 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 133 Vaccines cabt Pharmacology cabt Infection cabt Vaccins gtt Immune System physiopathology Vaccines Vaccines pharmacology Vaccines therapeutic use Impfstoff (DE-588)4026655-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Impfstoff (DE-588)4026655-2 s DE-604 Perlmann, Peter Sonstige oth Bergström, Tomas Sonstige oth Handbook of experimental pharmacology 133 (DE-604)BV002390716 133 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008261306&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Vaccines [with 20 tables] Handbook of experimental pharmacology Vaccines cabt Pharmacology cabt Infection cabt Vaccins gtt Immune System physiopathology Vaccines Vaccines pharmacology Vaccines therapeutic use Impfstoff (DE-588)4026655-2 gnd |
| subject_GND | (DE-588)4026655-2 (DE-588)4143413-4 |
| title | Vaccines [with 20 tables] |
| title_auth | Vaccines [with 20 tables] |
| title_exact_search | Vaccines [with 20 tables] |
| title_full | Vaccines [with 20 tables] contributors T. Bergström ... Ed. P. Perlmann and H. Wigzell |
| title_fullStr | Vaccines [with 20 tables] contributors T. Bergström ... Ed. P. Perlmann and H. Wigzell |
| title_full_unstemmed | Vaccines [with 20 tables] contributors T. Bergström ... Ed. P. Perlmann and H. Wigzell |
| title_short | Vaccines |
| title_sort | vaccines with 20 tables |
| title_sub | [with 20 tables] |
| topic | Vaccines cabt Pharmacology cabt Infection cabt Vaccins gtt Immune System physiopathology Vaccines Vaccines pharmacology Vaccines therapeutic use Impfstoff (DE-588)4026655-2 gnd |
| topic_facet | Vaccines Pharmacology Infection Vaccins Immune System physiopathology Vaccines pharmacology Vaccines therapeutic use Impfstoff Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008261306&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002390716 |
| work_keys_str_mv | AT perlmannpeter vaccineswith20tables AT bergstromtomas vaccineswith20tables |